Orbimed Advisors LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

Orbimed Advisors LLC raised its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 27.0% in the first quarter, Holdings Channel reports. The fund owned 1,475,403 shares of the company’s stock after buying an additional 313,600 shares during the period. Structure Therapeutics makes up approximately 1.3% of Orbimed Advisors LLC’s portfolio, making the stock its 17th biggest holding. Orbimed Advisors LLC’s holdings in Structure Therapeutics were worth $71,114,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in shares of Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after purchasing an additional 1,432,797 shares in the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after purchasing an additional 1,150,000 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Structure Therapeutics by 14.4% during the fourth quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock worth $354,006,000 after purchasing an additional 641,322 shares in the last quarter. BVF Inc. IL increased its holdings in Structure Therapeutics by 8.6% in the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after buying an additional 275,105 shares during the last quarter. Finally, Morgan Stanley increased its holdings in Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after buying an additional 1,510,093 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $49.12 on Monday. The firm’s fifty day moving average price is $45.42 and its 200 day moving average price is $55.80. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90. The company has a market capitalization of $3.49 billion, a price-to-earnings ratio of -56.46 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on GPCR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Canaccord Genuity Group initiated coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 price objective on the stock. HC Wainwright cut their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research report on Thursday, June 11th. Finally, Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.